This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023
1 min

Why we developed Nexviadyme®▼ (avalglucosidase alfa)

Author: Sanofi

Editorial team

  

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

In this video, find out how we used glycoengineering and chemical conjugation to help overcome the challenge of cellular delivery of acid alpha-glucosidase, by increasing the levels of bis-M6P1,4 compared to Myozyme (alglucosidase alfa).

Our commitment to rare diseases

Find out how we have led with science for over 30 years,5 and continue to bring innovation to people living with lysosomal storage disorders.

How Nexviadyme® was designed

Watch how we used preclinical mice models of Pompe to design Nexviadyme®, and improve maintenance of muscle strength compared to Myozyme®.1,3

1/2

Our commitment to rare diseases

Find out how we have led with science for over 30 years,5 and continue to bring innovation to people living with lysosomal storage disorders.

How Nexviadyme® was designed

Watch how we used preclinical mice models of Pompe to design Nexviadyme®, and improve maintenance of muscle strength compared to Myozyme®.1,3

References
  1. Sanofi. Nexviadyme (avalglucosidase alfa). Summary of Product Characteristics. 2023. Available at: https://www.medicines.org.uk/emc/product/14562/smpc#gref.

  2. Zhu Y, et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. The Biochemical Journal. 2005 Aug 1;389(Pt 3):619-628.

  3. Zhu Y, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Molecular Therapy. 2009 Jun;17(6):954-963.

  4. Chien YH, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. Journal of Pediatrics. 2015 Apr;166(4):985-91.e1-2.

  5. Mistry, P.K. et al. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence. Orphanet Journal of Rare Diseases. 2022;17:362.
     

MAT-XU-2302327 (v3.0) Date of preparation: December 2023